Cost-Effectiveness of Remote Symptom Monitoring During Adjuvant Endocrine Therapy in Breast Cancer
JAMA Network Open · 02.11.2026 · 9 (11) · e2641402
DOI: 10.1001/jamanetworkopen.2026.41402 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 02.11.2026. Verfasst von Xin Hu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Emory University, Atlanta, Georgia. Hauptthemen laut MEDLINE: Antineoplastic Agents, Hormonal, Breast Neoplasms. Die Arbeit nennt 58 Literaturangaben. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Importance Adjuvant endocrine therapy (AET) reduces recurrence and mortality for women with early-stage hormone receptor–positive breast cancer, yet long-term adherence is suboptimal, largely due to treatment-related symptoms. Remote patient monitoring (RPM) is a potential strategy to improve symptom management, but evidence of its cost-effectiveness is limited.
Objective
To evaluate the cost-effectiveness of RPM for women prescribed AET for early-stage breast cancer. Design, Setting, and Participants This economic evaluation used data from the THRIVE trial, which randomized adult women initiating AET to an application (app), the app with tailored feedback, or enhanced usual care (EUC) at a large cancer center with 14 clinics from November 15, 2018, to June 11, 2021. The intervention lasted 6 months, and participants were followed up for 12 months (completed September 19, 2022). Each of the 2 interventions was compared with EUC, with uncertainty assessed using probabilistic sensitivity analyses. Data analyses were performed from February 1, 2025, to September 2, 2026. Main Outcomes and Measures Primary outcomes included costs, which were captured during the 12-month study period from a societal perspective, including medical costs, patient time and travel costs, clinician time costs responding to alerts, and app costs; quality-adjusted life years (QALYs), derived from patient-reported 12-item Short Form Health Survey scores; incremental cost-effectiveness ratios; and incremental net monetary benefit.
Results
Of 304 participants randomized, 214 had complete data. The mean (SD) age was 58.9 (10.8) years. Mean (SD) total costs were highest for the EUC arm ($11 596.10 [$30 231.95]) compared with the app arm ($6682.15 [$12 963.34]; difference, −$4913.95 [95% CI, −$12 864.27 to $3036.37]) and app plus feedback arm ($11 407.85 [$47 068.42]; difference, −$188.25 [95% CI, −$12 830.16 to $12 453.66]). The mean (SD) estimated QALYs were similar across arms (app, 0.79 [012]; app plus feedback, 0.78 [0.13]; EUC, 0.78 [0.12]). This results in an incremental net monetary benefit of $5813.95 (95% uncertainty interval [UI], −$1860.00 to $16 492.58) for app group and $88.25 (95% UI, −$14 781.73 to $13 849.34) for the app plus feedback group at $100 000 per QALY. Probabilistic sensitivity analyses suggest that the app intervention had a 68.2% to 78.1% probability of being cost-effective compared with EUC across a willingness-to-pay threshold of $0 to $200 000 per QALY, while the app plus feedback intervention had a 53.6% to 70.8% probability of being cost-effective. Conclusions and Relevance In this economic evaluation of RPM for women receiving AET, app-only RPM showed lower costs with similar QALY compared with EUC. Its simpler design may also be more readily scalable than the app plus feedback intervention, supporting its potential as a pragmatic, value-based supportive care strategy in oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Emory University, Atlanta, Georgia.
- Department of Health Policy and Management, Emory University, Atlanta, Georgia.
- Winship Cancer Institute, Emory University, Atlanta, Georgia.
- West Cancer Center and Research Institute, Germantown, Tennessee.
- College of Medicine, University of Tennessee Health Science Center, Memphis.
- School of Public Health, Augusta University, Augusta, Georgia.
Förderung
- NCI NIH HHS
Zitieren
APA
Hu, X., Yang, F., Curry, A. N., Vidal, G. A., Waters, T. M., Robichaux, C., Schwartzberg, L. S., & Graetz, I. (2026). Cost-Effectiveness of Remote Symptom Monitoring During Adjuvant Endocrine Therapy in Breast Cancer. JAMA Network Open, 9(11), e2641402. https://doi.org/10.1001/jamanetworkopen.2026.41402
Vancouver
Hu X, Yang F, Curry AN, Vidal GA, Waters TM, Robichaux C, et al. Cost-Effectiveness of Remote Symptom Monitoring During Adjuvant Endocrine Therapy in Breast Cancer. JAMA Network Open. 2026;9(11):e2641402. doi:10.1001/jamanetworkopen.2026.41402
BibTeX
@article{Hu2026,
author = {Hu, Xin and Yang, Freddie and Curry, Andrea N and Vidal, Gregory A and Waters, Teresa M and Robichaux, Chad and Schwartzberg, Lee S and Graetz, Ilana},
title = {Cost-Effectiveness of Remote Symptom Monitoring During Adjuvant Endocrine Therapy in Breast Cancer},
journal = {JAMA Network Open},
year = {2026},
volume = {9},
number = {11},
pages = {e2641402},
doi = {10.1001/jamanetworkopen.2026.41402}
}
EUVIMED